The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the V.sub.H, V.sub.L and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-ACTH antibodies and binding fragments thereof for the diagnosis, assessment, prevention and treatment of diseases and disorders associated with ACTH, such as Cushing's Disease, Cushing's Syndrome, Parkinson's disease, obesity, diabetes, sleep disorders depression, anxiety disorders, cancer, muscle atrophy, hypertension, hyperinsulinemia, cognitive dysfunction, Alzheimer's disease, galactorrhea, stress related conditions, cardiac conditions, metabolic syndrome, hyperaldosteronism, Conn's syndrome and familial hyperaldosteronism.

The present invention relates to a novel immunoglobulin Fc domain variant protein and use thereof, and when expressed in the form of a fusion protein with another biologically active protein, an immunoglobulin Fc domain variant protein according to an embodiment of the present invention can prolong the half-life in vivo of the biologically active protein as well as effectively suppress effector functions such as ADCC or CDC to minimize unexpected side effects.

A variable region sequence of a specific antibody against clothianidin is provided. A gene encoding a heavy chain variable region of the antibody has an amino acid sequence shown in SEQ ID NO: 2. An intact recombinant antibody against clothianidin is provided. The intact recombinant antibody includes a heavy chain constant region, a heavy chain variable region, a light chain constant region and a light chain variable region, wherein a gene encoding the heavy chain variable region has an amino acid sequence shown in SEQ ID NO: 2. An immunostrip containing the antibody for rapid detection of clothianidin residue is also provided. The sequence genes obtained are linked to an expression vector containing a heavy chain constant region gene and a light chain constant region gene, respectively, and an intact recombinant antibody is expressed and obtained by using mammalian cells with a double-plasmid system.

An scFv-Fc dimer binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGFβ1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.

The invention provides novel heterodimeric proteins including heterodimeric antibodies.

The present invention provides a polypeptides comprising a heavy chain domain 2 (HD2) from IgM or IgE and at least one pharmaceutically active moiety, complexes thereof and their use for therapy and prophylaxis.

The present disclosure provides anti-CTLA-4 antibody polypeptides, polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

Provided is a binding protein that binds CD40 and is an agonist thereof. In a particular embodiment the invention provides an agonistic anti-CD40 antibody. Also provided are bispecific conjugates comprising the binding protein, and complexes comprising the bispecific conjugates non-covalently bound to a tag construct comprising an antigen, for antigen delivery to immune cells. Medical uses of the binding proteins, conjugates and complexes of the invention are also provided.

The present invention provides multispecific antibodies, and antigen binding fragments thereof, that potently neutralize a cytokine and that may thus be useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases. In particular, the present invention provides a multispecific antibody, or an antigen binding fragment thereof, comprising at least two different domains specifically binding to at least two different, non-overlapping sites in a cytokine and an Fc moiety. The invention also relates to nucleic acids that encode such antibodies and antibody fragments and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of inflammatory and/or autoimmune diseases.

Provided in the present invention is a method for constructing a multispecific antibody. The method comprises the steps of: (i) constructing a first polynucleotide and a second polynucleotide, respectively, wherein the first polynucleotide and the second polynucleotide respectively encode a first polypeptide containing a CL region and a second polypeptide containing a CH1 region, and a disulfide bond may be formed between the CL region of the first polypeptide and the CH1 region of the second polypeptide, such that the antibody has a heterodimeric form; and (ii) expressing the first polynucleotide and the second polynucleotide to obtain the first polypeptide and the second polypeptide, and dimerize the first polypeptide and the second polypeptide to form a multispecific antibody with a heterodimeric form. The antibody of the present invention can simultaneously bind to different targets and maintain the binding activity of the original antibody, which plays a role when the target is a membrane surface receptor or a target in a solution and has a biological activity against multiple targets.